Get started
Author

Shireen Sirhan

Observed names: S Sirhan, S. Sirhan
ORCID: 0000-0003-4957-4307
Observed ORCID: 0000-0003-4957-4307
OpenAlex ID: A5067675521
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
2019 · Natasha Szuber, Mythri Mudireddy, et al. · Mayo Clinic Proceedings · 168
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
2016 · Vikas Gupta, Ruben A. Mesa, et al. · Haematologica · 98
PDF
Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia
2005 · Ayalew Tefferi, Shireen Sirhan, et al. · British Journal of Haematology · 91
PDF
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
2017 · A Pardanani, J Gotlib, et al. · Leukemia · 76
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients
2004 · Brijesh Arora, Shireen Sirhan, et al. · British Journal of Haematology · 49
PDF
Red cell mass and plasma volume measurements in polycythemia:
2005 · Shireen Sirhan, Virgil F. Fairbanks, et al. · Cancer · 46
PDF
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
2019 · John Mascarenhas, Marina Kremyanskaya, et al. · Blood · 45
Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis
2013 · Animesh Pardanani, Jason Gotlib, et al. · Blood · 45
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
2008 · Shireen Sirhan, Terra L. Lasho, et al. · American Journal of Hematology · 39
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs)
2016 · Lambert Busque, Anna Porwit, et al. · American Journal of Clinical Pathology · 38
Artificial intelligence in hematology
2025 · Aziz Nazha, Olivier Elemento, et al. · Blood · 36
PDF
An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,
2011 · Animesh Pardanani, Jason Gotlib, et al. · Blood · 36
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
2021 · Eliane Nguyen, Michaël Harnois, et al. · Blood Cancer Journal · 35
PDF
3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
2018 · Natasha Szuber, Mythri Mudireddy, et al. · Blood · 35
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
2020 · Vikas Gupta, Sonia Cerquozzi, et al. · JCO Oncology Practice · 33
Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.
2011 · A. D. Pardanani, D. Caramazza, et al. · Journal of Clinical Oncology · 30
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
2024 · Ayalew Tefferi, Giovanni Barosi, et al. · Blood · 29
Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
2012 · Animesh Pardanani, Jason Gotlib, et al. · Blood · 21
Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis
2008 · Ayalew Tefferi, Shireen Sirhan, et al. · Leukemia Research · 20
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
2024 · Claire N. Harrison, Alessandro M. Vannucchi, et al. · Advances in Therapy · 17
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study
2024 · James T. England, Natasha Szuber, et al. · Leukemia · 16
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
2015 · Shireen Sirhan, Lambert Busque, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates.
2005 · Shireen Sirhan, Terra L Lasho, et al. · PubMed · 12
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study
2023 · Dawn Maze, Murat O. Arcasoy, et al. · Bone Marrow Transplantation · 10
PDF
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera
2025 · John Mascarenhas, Prithviraj Bose, et al. · Acta Haematologica · 7
Works count: 62
Citation count: 1,127
H-index: 19
I10-index: 24
Year
Topic
Type